---
title: "Hengrui Pharma surges 11% as Q3 profit beats estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303309080.md"
description: "Hengrui Pharma surged 11.31% to HK$49.78 as Q3 net income jumped 88.92% to 2.458 billion yuan, beating estimates."
datetime: "2026-10-28T01:32:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303309080.md)
  - [en](https://longbridge.com/en/news/303309080.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303309080.md)
generator: "portal-rs"
---

# Hengrui Pharma surges 11% as Q3 profit beats estimates

Hengrui Pharma (1276.HK) surged more than **11%** in Hong Kong trading to **HK$49.78**.

The company reported third-quarter revenue of **8.953 billion yuan**, up 20.55% year-over-year, while net income attributable to shareholders rose 88.92% to **2.458 billion yuan**, topping market expectations. Innovative drug sales reached **13.871 billion yuan** in the first nine months, up 17.05% from a year earlier and accounting for **64.59%** of total pharmaceutical revenue; licensing income climbed 31.12% to **2.781 billion yuan**, driving overall performance back to double-digit growth.

Separately, Hengrui received approval for a new indication of its Class 1 innovative drug remimazolam tosilate for injection, intended for sedation during mechanical ventilation in intensive care units, with cumulative R&D investment of approximately **223 million yuan**. Additionally, three drug candidates — SHR-2005 injection, SHR-1501 for injection and adebrelimab injection — received clinical trial approval from China’s National Medical Products Administration.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Hengrui Announces Drug Inclusions in China’s 2026 NRDL](https://longbridge.com/en/news/305570916.md)
- [Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals](https://longbridge.com/en/news/303205414.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**